Spironolactone in thiazide-induced hypokalaemia: variable response between patients.
1 The influence of spironolactone 25, 50, 100 and 200 mg daily, and placebo, on plasma potassium and other variables was examined in a random crossover study of 15 hypertensive patients taking bendrofluazide 10 mg daily. 2 Spironolactone produced significant dose-related increases in plasma potassium and aldosterone, and reductions in plasma sodium and bicarbonate. 3 In 14 compliant patients plasma concentrations of the major metabolite canrenone were related linearly to the dose of spironolactone, and there was less than twofold variation between patients. The plasma canrenone concentration correlated negatively with body weight (r = -0.77, P less than 0.001). 4 The plasma potassium response to spironolactone varied sevenfold between compliant patients. The response correlated negatively with placebo plasma potassium (r = -0.62, P less than 0.02), positively with plasma canrenone (r = +0.55, P less than 0.05), but was unrelated to plasma aldosterone (r = -0.22). In one patient relative resistance to spironolactone was attributed to exaggerated secondary hyperaldosteronism induced by the drug. 5 The variability in response to spironolactone between patients is such that fixed dose thiazide-spironolactone combination tablets are unlikely to prevent hypokalaemia reliably.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D001581:Benzothiadiazines; D002192:Canrenone / Q000097:blood; D004232:Diuretics; D004573:Electrolytes / Q000097:blood; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects*; D013148:Spironolactone / Q000627:therapeutic use*
D001581:Benzothiadiazines; D004232:Diuretics; D004573:Electrolytes; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D000450:Aldosterone; D002192:Canrenone; D011188:Potassium